Poly-gamma-glutamic acid-containing vaccine

Drug Profile

Poly-gamma-glutamic acid-containing vaccine

Alternative Names: BLS-PGA-C10

Latest Information Update: 15 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bioleaders Corporation
  • Developer Bioleaders Corporation; CJ HealthCare; Tianjin International Joint Academy of Biotechnology and Medicine
  • Class Cancer vaccines; Glutamates; Peptides
  • Mechanism of Action Immunostimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Cervical intraepithelial neoplasia

Most Recent Events

  • 06 Jun 2017 Efficacy data from a phase IIb trial in Cervical intraepithelial neoplasia presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
  • 06 Jun 2017 BioLeaders Corporation initiates enrolment in a phase IIb trial for Cervical intraepithelial neoplasia in South Korea before June 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top